Log in or Sign up for Free to view tailored content for your specialty!
Obesity News
Genetic data explored to help tailor obesity treatment, personalize care
SAN DIEGO — The future of obesity management may include using personal genetic profiles to develop individualized prevention strategies and personalized treatment plans, according to a speaker at ObesityWeek 2022.
Glucagon/GLP-1 dual receptor agonist bests 1 mg semaglutide for weight loss: Phase 2 trial
SAN DIEGO — A weekly glucagon/GLP-1 dual receptor agonist conferred greater weight loss than 1 mg semaglutide at 16 weeks among adults with type 2 diabetes, according to findings from a phase 2 trial.
Log in or Sign up for Free to view tailored content for your specialty!
Virtual diabetes-tailored weight management program benefits adults with type 2 diabetes
SAN DIEGO — A virtual diabetes-tailored weight management program resulted in beneficial and clinically meaningful effects on glucose levels, body weight and diabetes distress among adults with type 2 diabetes.
Significant weight loss among patients with hypothalamic obesity seen with setmelanotide
SAN DIEGO — Treatment with the melanocortin-4 receptor agonist setmelanotide was associated with significant weight loss among patients with hypothalamic obesity, according to a presenter at ObesityWeek.
More adipose tissue increases breast cancer risk after menopause
SAN DIEGO — Higher amounts of visceral and subcutaneous adipose tissue are associated with an increased risk for breast cancer among postmenopausal women, according to a presenter at ObesityWeek 2022.
Infants who breastfeed for shorter duration more likely to have obesity during childhood
SAN DIEGO — Infants exposed to gestational diabetes who breastfeed for less than 6 months and drink sugar-sweetened beverages or natural fruit juice are more likely to have obesity during childhood, according to a presenter.
Weight gain during adulthood may vary based on obesity phenotypes during adolescence
SAN DIEGO — Adolescents with overweight or obesity may have different degrees of weight gain during adulthood based on their obesity phenotype, according to findings presented at ObesityWeek 2022.
‘Mind-blowing’ weight loss with semaglutide extends to adolescents with obesity
SAN DIEGO — Adolescents with obesity had a BMI reduction of 16.1% at 68 weeks with once-weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention, results similar to those seen with adults, according to top-line results presented at ObesityWeek 2022.
FDA grants breakthrough therapy designation to setmelanotide for hypothalamic obesity
The FDA has granted breakthrough therapy designation to setmelanotide for patients with hypothalamic obesity, according to a company press release.
New hormone-based therapies poised to expand obesity treatment options
SAN DIEGO — Multiple new anti-obesity medications currently in the pipeline could expand treatment options for the disease in the coming years, according to a speaker at ObesityWeek 2022.